Apolipoprotein-mediated cellular cholesterol/phospholipid efflux and plasma high density lipoprotein level in mice

Biochimica et Biophysica Acta - Molecular and Cell Biology of Lipids

Volumn 1485, Issue 2-3, 2000, Pages 199-213

  Tsujita, Maki ^a   Tomimoto, Shigehiro ^a   Okumura Noji, Kuniko ^a   Okazaki, Mitsuyo ^b   Yokoyama, Shinji ^a  

^a NAGOYA CITY UNIV MEDICAL SCHOOL   (Japan)

^b Laboratory of Chemistry   (Japan)

Author keywords

ApoA I; Cholesterol efflux; High density lipoprotein; Probucol

Indexed keywords

ABC TRANSPORTER; APOLIPOPROTEIN; APOLIPOPROTEIN A1; APOLIPOPROTEIN E; CHOLESTEROL; CHOLESTEROL ESTER TRANSFER PROTEIN; HIGH DENSITY LIPOPROTEIN; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LOW DENSITY LIPOPROTEIN; PHOSPHATIDYLCHOLINE STEROL ACYLTRANSFERASE; PHOSPHOLIPID; PHOSPHOLIPID TRANSFER PROTEIN; PROBUCOL; SCAVENGER RECEPTOR;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; CHOLESTEROL METABOLISM; CHOLESTEROL TRANSPORT; CONTROLLED STUDY; LIPOPROTEIN BLOOD LEVEL; MALE; MOUSE; NONHUMAN; PERITONEUM MACROPHAGE; PHOSPHOLIPID TRANSFER; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; TANGIER DISEASE;

ANIMALS; ANTICHOLESTEREMIC AGENTS; APOLIPOPROTEIN A-I; CHOLESTEROL; CHOLESTEROL ESTERS; GENE EXPRESSION; LIPOPROTEINS, HDL; LIPOPROTEINS, LDL; MACROPHAGES, PERITONEAL; MALE; MICE; MICE, INBRED BALB C; PHOSPHOLIPIDS; PROBUCOL; RNA, MESSENGER; TISSUE DISTRIBUTION;

ANIMALIA;

EID: 0034737924     PISSN: 13881981     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1388-1981(00)00061-5     Document Type: Article

References (53)

1. Li H., Reddick R.L., Maeda N. Lack of apoA-I is not associated with increased susceptibility to atherosclerosis in mice. Arterioscler. Thromb. 13:1993;1814-1821.
2. Zhu Y., Bellosta S., Langer C., Bernini F., Pitas R.E., Mahley R.W., Assmann G., von Eckardstein A. Low-dose expression of a human apolipoprotein E transgene in macrophages restores cholesterol efflux capacity of apolipoprotein E-deficient mouse plasma. Proc. Natl. Acad. Sci. USA. 95:1998;7585-7590.
3. Jiang X.-c., Bruce C., Mar J., Lin M., Ji Y., Francone O.L., Tall A.R. Targeted mutation of plasma phospholipid transfer protein gene markedly reduces high-density lipoprotein levels. J. Clin. Invest. 103:1999;907-914.
4. Sakai N., Vaisman B.L., Koch C.A., Hoyt R.F. Jr., Meyn S.M., Talley G.D., Paiz J.A., Brewer H.B. Jr., Santamarina-Fojo S. Targeted disruption of the mouse lecithin:cholesterol acyltransferase (LCAT) gene: Generation of a new animal model for human LCAT deficiency. J. Biol. Chem. 272:1997;7506-7510.
5. Ng D.S., Francone O.L., Forte T.M., Zhang J., Haghpassand M., Rubin E.M. Disruption of the murine lecithin:cholesterol acyltransferase gene causes impairment of adrenal lipid delivery and up-regulation of scavenger receptor class B type I. J. Biol. Chem. 272:1997;15777-15781.
6. Agellon L.B., Walsh A., Hayek T., Moulin P., Jiang X.C., Shelanski S.A., Breslow J.L., Tall A.R. Reduced high density lipoprotein cholesterol in human cholesteryl ester transfer protein transgenic mice. J. Biol. Chem. 266:1991;10796-10801.
7. Kozarsky K.F., Donahee M.H., Rigotti A., Iqbal S.N., Edelman E.R., Krieger M. Overexpression of the HDL receptor SR-B1 alters plasma HDL and bile cholesterol levels. Nature. 387:1997;414-417.
8. Hara H., Yokoyama S. Interaction of free apolipoproteins with macrophages: Formation of high density lipoprotein-like lipoproteins and reduction of cellular cholesterol. J. Biol. Chem. 266:1991;3080-3086.
9. Bielicki J.K., Johnson W.J., Weinberg R.B., Glick J.M., Rothblat G.H. Efflux of lipid from fibroblasts to apolipoproteins: dependence on elevated levels of cellular unesterified cholesterol. J. Lipid Res. 33:1992;1699-1709.
10. Forte T.M., Goth-Goldstein R., Nordhausen R.W., McCall M.R. Apolipoprotein A-I-cell membrane interaction: extracellular assembly of heterogeneous nascent HDL particles. J. Lipid Res. 34:1993;317-324.
11. Mendez A.J., Anantharamaiah G.M., Segrest J.P., Oram J.F. Synthetic amphipathic helical peptides that mimic apolipoprotein A-I in clearing cellular cholesterol. J. Clin. Invest. 94:1994;1698-1705.
12. Zhang W.-Y., Gaynor P.M., Kruth H.S. Apolipoprotein E produced by human monocyte-derived macrophages mediates cholesterol efflux that occurs in the absence of added cholesterol acceptors. J. Biol. Chem. 271:1996;28641-28646.
13. Mendez A.J., Uint L. Apolipoprotein-mediated cellular cholesterol and phospholipid efflux depend on a functional Golgi apparatus. J. Lipid Res. 37:1996;2510-2524.
14. Yokoyama S. Apolipoprotein-mediated cellular cholesterol efflux. Biochim. Biophys. Acta. 1392:1998;1-15.
15. Francis G.A., Knopp R.H., Oram J.F. Defective removal of cellular cholesterol and phospholipids by apolipoprotein A-I in Tangier disease. J. Clin. Invest. 96:1995;78-87.
16. Remaley A.T., Schumacher U.K., Stonik J.A., Farsi B.D., Nazih H., Brewer H.B. Jr. Decreased reverse cholesterol transport from Tangier disease fibroblasts: Acceptor specificity and effect of brefeldin on lipid efflux. Arterioscler. Thromb. Vasc. Biol. 17:1997;1813-1821.
17. Brooks-Wilson A., Marcil M., Clee S.M., Zhang L.-H., Roomp K., vanDam M., Yu L., Brewer C., Collins J.A., Molhuizen H.O.F., Loubser O., Ouelette B.F.F., Fichter K., Ashbourne-Excoffon K.J.D., Sensen C.W., Scherer S., Mott S., Denis M., Martindale D., Frohlich J., Morgan K., Koop B., Pimstone S., Kastelein J.J.P., Genest J. Jr., Hayden M.R. Mutations in ABC 1 in Tangier disease and familial high-density lipoprotein deficiency. Nat. Genet. 22:1999;336-345.
18. Bodzioch M., Orso E., Klucken J., Langmann T., Böttcher A., Diederich W., Drobnik W., Barlage S., Büchler C., Porsch-Özcürümez M., Kaminski W.E., Hahmann H.W., Oette K., Rothe G., Aslanidis C., Lackner K.J., Schmitz G. The gene encoding ATP-binding cassette transporter 1 is mutated in Tangier disease. Nat. Genet. 22:1999;347-351.
19. Rust S., Rosier M., Funke H., Real J., Amoura Z., Piette J.-C., Deleuze J.-F., Brewer H.B., Duverger N., Denefle P., Assmann G. Tangier disease is caused by mutations in the gene encoding ATP binding-cassette transporter 1. Nat. Genet. 22:1999;352-355.
20. Remaley A.T., Rust S., Rosier M., Knapper C., Naudin L., Broccardo C., Peterson K.M., Koch C., Arnould I., Prades C., Duverger N., Funke H., Assman G., Dinger M., Dean M., Chimini G., Santamarina-Fojo S., Fredrickson D.S., Denefle P., Brewer H.B. Jr. Human ATP-binding cassette transporter 1 (ABC1): Genomic organization and identification of the genetic defect in the original Tangier disease kindred. Proc. Natl. Acad. Sci. USA. 96:1999;12685-12690.
21. Lawn R.M., Wade D.P., Garvin M.R., Wang X., Schwartz K., Porter J.G., Seilhamer J.J., Vaughan A.M., Oram J.F. The Tangier disease gene product ABC1 controls the cellular apolipoprotein-mediated lipid removal pathway. J. Clin. Invest. 104:1999;R25-R31.
22. Tsujita M., Yokoyama S. Selective inhibition of free apolipoprotein-mediated cellular lipid efflux by probucol. Biochemistry. 35:1996;13011-13020.
23. Sakr S.W., Williams D.L., Stoudt G.W., Phillips M.C., Rothblat G.H. Induction of cellular cholesterol efflux to lipid-free apolipoprotein A-I by cAMP. Biochim. Biophys. Acta. 1438:1999;85-98.
24. Yokoyama S., Yamamoto A., Kurasawa T. A little more information about aggravation of probucol-induced HDL-reduction by clofibrate. Atherosclerosis. 70:1988;179-181.
25. Satonin D.K., Coutant J.E. Comparison of gas chromatography and high-performance liquid chromatography for the analysis of probucol in plasma. J. Chromatogr. 380:1986;401-406.
26. M. Okazaki, K. Sasamoto, T. Muramatsu, S. Hosaki, Analysis of plasma lipoproteins by gel permeation chromatography, in: N. Rifai, G.R. Warnick, M.H. Dominiczak (Eds.), Handbook of Lipoprotein Testing, AACC, Washington, DC, 1997, pp. 531-548.
27. Francis G.A., Oram J.F., Heinecke J.W., Bierman E.L. Oxidative tyrosylation of HDL enhances the depletion of cellular cholesteryl esters by a mechanism independent of passive sterol desorption. Biochemistry. 35:1996;15188-15197.
28. McFarlane A.S. Efficient trace-labelling of proteins with Iodine. Nature. 182:1958;53.
29. Ko K.W.S., Oikawa K., Ohnishi T., Kay C.M., Yokoyama S. Purification, characterization, and conformational analysis of rabbit plasma lipid transfer protein. Biochemistry. 32:1993;6729-6736.
30. Czarnecka H., Yokoyama S. Regulation of lecithin-cholesterol acyltransferase reaction by acyl acceptors and demonstration of its 'idling' reaction. J. Biol. Chem. 268:1993;19334-19340.
31. Roheim P.S., Rachmilewitz D., Stein O., Stein Y. Metabolism of iodinated high density lipoproteins in rat: I. Half-life in the circulation and uptake by organs. Biochim. Biophys. Acta. 248:1971;315-329.
32. Richard B.M., Pfeuffer M.A., Pittman R.C. Transport of HDL cholesterol esters to the liver is not diminished by probucol treatment in rats. Arterioscler. Thromb. 12:1992;862-869.
33. Schaefer E.J., Blum C.B., Levy R.I., Jenkins L.L., Alaupovic P., Foster D.M., Brewer H.B. Jr. Metabolism of high-density lipoprotein apolipoproteins in Tangier disease. N. Engl. J. Med. 299:1978;905-910.
34. Tangier). J. Clin. Invest. 70:1982;934-945.
35. Brinton E.A., Eisenberg S., Breslow J.L. Increased apoA-I and apoA-II fractional catabolic rate in patients with low high density lipoprotein-cholesterol levels with or without hypertriglyceridemia. J. Clin. Invest. 87:1991;536-544.
36. Brinton E.A., Eisenberg S., Breslow J.L. Human HDL cholesterol levels are determined by apoA-I fractional catabolic rate, which correlates inversely with estimates of HDL particle size. Effect of gender, hepatic and lipoprotein lipases, triglyceride and insulin levels, and body fat distribution. Arterioscler. Thromb. 14:1994;707-720.
37. Batal R., Tremblay M., Krimbou L., Mamer O., Davignon J., Genest J. Jr., Cohn J.S. Familial HDL deficiency characterized by hypercatabolism of mature apoA-I but not proapoA-I. Arterioscler. Thromb. Vasc. Biol. 18:1998;655-664.
38. Hayek T., Chajek-Shaul T., Walsh A., Azrolan N., Breslow J.L. Probucol decreases apolipoprotein A-I transport rate and increases high density lipoprotein cholesteryl ester fractional catabolic rate in control and human apolipoprotein A-I transgenic mice. Arterioscler. Thromb. 11:1991;1295-1302.
39. Rinninger F., Wang N., Ramakrishnan R., Jiang X.C., Tall A.R. Probucol enhances selective uptake of HDL-associated cholesteryl esters in vitro by a scavenger receptor B-I-dependent mechanism. Arterioscler. Thromb. Vasc. Biol. 19:1999;1325-1332.
40. Franceschini G., Sirtori M., Vaccarino V., Gianfranceschi G., Rezzonico L., Chiesa G., Sirtori C.R. Mechanisms of HDL reduction after probucol: Changes in HDL subfractions and increased reverse cholesteryl ester transfer. Arteriosclerosis. 9:1989;462-469.
41. McPherson R., Hogue M., Milne R.W., Tall A.R., Marcel Y.L. Increase in plasma cholesteryl ester transfer protein during probucol treatment. Relation to changes in high density lipoprotein composition. Arterioscler. Thromb. 11:1991;476-481.
42. G. Assmann, A. von Eckardstein, H. B. J. Brewer, Familial high density lipoprotein deficiency: Tangier disease, in: C.R. Scriver, A.L. Beaudet, W.S. Sly, D. Valle (Eds.), The Metabolic and Molecular Bases of Inherited Disease, McGraw-Hill, Health Profession Division, New York, 1995, pp. 2053-2072.
43. Yamamoto A., Matsuzawa Y., Yokoyama S., Funahashi T., Yamamura T., Kishino B. Effects of probucol on xanthomata regression in familial hypercholesterolemia. Am. J. Cardiol. 57:1986;29H-35H.
44. Kita T., Nagano Y., Yokode M., Ishii K., Kume N., Ooshima A., Yoshida H., Kawai C. Probucol prevents the progression of atherosclerosis in Watanabe heritable hyperlipidemic rabbit, an animal model for familial hypercholesterolemia. Proc. Natl. Acad. Sci. USA. 84:1987;5928-5931.
45. Sasahara M., Raines E.W., Chait A., Carew T.E., Steinberg D., Wahl P.W., Ross R. Inhibition of hypercholesterolemia-induced atherosclerosis in the nonhuman primate by probucol. 1. Is the extent of atherosclerosis related to resistance of LDL to oxidation? J. Clin. Invest. 94:1994;155-164.
46. Tardif J.-C., Cote G., Lesperance J., Bourassa M., Lambert J., Doucet S., Bilodeau L., Nattel S., deGuise P. Probucol and multivitamins in the prevention of restenosis after coronary angioplasty. N. Engl. J. Med. 337:1997;365-372.
47. Zhang S.H., Reddick R.L., Avdievich E., Surles L.K., Jones R.G., Reynolds J.B., Quarfordt S.H., Maeda N. Paradoxical enhancement of atherosclerosis by probucol treatment in apolipoprotein E-deficient mice. J. Clin. Invest. 99:1997;2858-2866.
48. Cynshi O., Kawabe Y., Suzuki T., Takashima Y., Kaise H., Nakamura M., Ohba Y., Kato Y., Tamura K., Hayasaka A., Higashida A., Sakaguchi H., Takeya M., Takahashi K., Inoue K., Noguchi N., Niki E., Kodama T. Antiatherogenic effects of the antioxidant BO-653 in three different animal models. Proc. Natl. Acad. Sci. USA. 95:1998;10123-10128.
49. 2b by probucol partly explains the failure of the drug to affect femoral atheroscelrosis in subjects with hypercholesterolemia: a probucol quantitative regression swedish trial (PQRST) report. Arterioscler. Thromb. Vasc. Biol. 15:1995;1049-1056.
50. Hara H., Yokoyama S. Role of apolipoproteins in cholesterol efflux from macrophages to lipid microemulsion: Proposal of a putative model for the pre-β high-density lipoprotein pathway. Biochemistry. 31:1992;2040-2046.
51. Hara H., Hara H., Komaba A., Yokoyama S. α-Helical requirements for free apolipoproteins to generate HDL and to induce cellular lipid efflux. Lipids. 27:1992;302-304.
52. Li Q., Komaba A., Yokoyama S. Cholesterol is poorly available for free apolipoprotein-mediated cellular lipid efflux from smooth muscle cells. Biochemistry. 32:1993;4597-4603.
53. Li Q., Tsujita M., Yokoyama S. Selective down-regulation by protein kinase C inhibitors of apolipoprotein-mediated cellular cholesterol efflux in macrophages. Biochemistry. 36:1997;12045-12052.